Cost-Effectiveness of Dabigatran (150 mg Twice Daily) and Warfarin in Patients ≥ 65 Years With Nonvalvular Atrial Fibrillation

about

Reimagining Anticoagulation Clinics in the Era of Direct Oral Anticoagulants

P2860

Q36693080-59156E0D-3499-4D79-ABF0-448457EBF61D

P2860

Cost-Effectiveness of Dabigatran (150 mg Twice Daily) and Warfarin in Patients ≥ 65 Years With Nonvalvular Atrial Fibrillation

Item

http://www.wikidata.org/entity/Q36657598

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Cost-Effectiveness of Dabigatr ...... onvalvular Atrial Fibrillation

@ast

Cost-Effectiveness of Dabigatr ...... onvalvular Atrial Fibrillation

@en

type

Item

label

Cost-Effectiveness of Dabigatr ...... onvalvular Atrial Fibrillation

@ast

Cost-Effectiveness of Dabigatr ...... onvalvular Atrial Fibrillation

@en

prefLabel

Cost-Effectiveness of Dabigatr ...... onvalvular Atrial Fibrillation

@ast

Cost-Effectiveness of Dabigatr ...... onvalvular Atrial Fibrillation

@en

P1476

Cost-Effectiveness of Dabigatr ...... onvalvular Atrial Fibrillation

@en

P2093

Brian M Salata

http://www.w3.org/2001/XMLSchema#string

David W Hutton

http://www.w3.org/2001/XMLSchema#string

Deborah A Levine

http://www.w3.org/2001/XMLSchema#string

Geoffrey D Barnes

http://www.w3.org/2001/XMLSchema#string

James B Froehlich

http://www.w3.org/2001/XMLSchema#string

P2860

Dabigatran versus warfarin in patients with atrial fibrillation

Long-term economic outcomes associated with intensive versus moderate lipid-lowering therapy in coronary artery disease: results from the Treating to New Targets (TNT) Trial.

Patient time requirements for anticoagulation therapy with warfarin.

The cost-effectiveness of different management strategies for patients on chronic warfarin therapy.

Risk factors for intracerebral hemorrhage in the general population: a systematic review.

Dabigatran etexilate versus warfarin in management of non-valvular atrial fibrillation in UK context: quantitative benefit-harm and economic analyses

Updating cost-effectiveness--the curious resilience of the $50,000-per-QALY threshold.

Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation.

Risks for stroke, bleeding, and death in patients with atrial fibrillation receiving dabigatran or warfarin in relation to the CHADS2 score: a subgroup analysis of the RE-LY trial.

Cost-effectiveness of dabigatran compared with warfarin for patients with atrial fibrillation in Sweden.

P304

54-60

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.AMJCARD.2015.09.048

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

117

http://www.w3.org/2001/XMLSchema#string

P577

2015-10-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26552509

http://www.w3.org/2001/XMLSchema#string

P932

4780215

http://www.w3.org/2001/XMLSchema#string

Cost-Effectiveness of Dabigatran (150 mg Twice Daily) and Warfarin in Patients ≥ 65 Years With Nonvalvular Atrial Fibrillation

about

P2860

P2860

Cost-Effectiveness of Dabigatran (150 mg Twice Daily) and Warfarin in Patients ≥ 65 Years With Nonvalvular Atrial Fibrillation

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P932